Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boston Scientific Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Paroxysmal, persistent or permanent non-valvular AF
Eligible for long-term warfarin therapy
Eligible to come off warfarin therapy
Calculated CHADS2 score of 2 or greater. Also patients with a CHADS2 score of 1 may be included if any of the following apply:
* Female age 75 or older
* Baseline LVEF ≥ 30 and \< 35%
* Aged 65-74 and has diabetes or coronary artery disease
* Aged 65 or greater and has congestive heart failure
You may not be if
Contraindicated/allergic to aspirin
Indicated for clopidogrel therapy or has taken clopidogrel within 7 days prior to enrollment
History of atrial septal repair or has an ASD/PFO device
Implanted mechanical valve prosthesis
NYHA Class IV CHF
Resting heart rate \> 110 bpm
Participated previously in the PROTECT AF or CAP Registry studies
LVEF \< 30%
Existing pericardial effusion \> 2mm
High risk PFO
Significant mitral valve stenosis
Complex atheroma with mobile plaque of the descending aorta and/or aortic arch
Cardiac tumor
Clareo Health | Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
